Inhaled AAT (KMA-001)
Alpha-1 Antitrypsin Deficiency (AATD)
Key Facts
About Kamada
Kamada is a vertically integrated biopharmaceutical company with a dual focus on commercial plasma-derived products and a pipeline of innovative therapeutics. Its flagship product, Glassia®, is an FDA-approved intravenous treatment for alpha-1 antitrypsin deficiency. The company leverages its manufacturing expertise to advance a pipeline of inhaled and plasma-derived therapies, while also engaging in strategic partnerships and contract development and manufacturing (CDMO) services.
View full company profileAbout Kamada
Kamada is a vertically integrated biopharmaceutical company with a dual focus on commercial plasma-derived products and a pipeline of innovative therapeutics. Its flagship product, Glassia®, is an FDA-approved intravenous treatment for alpha-1 antitrypsin deficiency. The company leverages its manufacturing expertise to advance a pipeline of inhaled and plasma-derived therapies, while also engaging in strategic partnerships and contract development and manufacturing (CDMO) services.
View full company profileTherapeutic Areas
Other Alpha-1 Antitrypsin Deficiency (AATD) Drugs
| Drug | Company | Phase |
|---|---|---|
| BEAM-302 | Beam Therapeutics | Preclinical |
| WVE-006 | WaVe Life Sciences | Phase 1/2 |
| INBRX-101 | Inhibrx Biosciences | Phase 2 |
| Glassia® (IV AAT) | Kamada | Approved |
| GalNAc Program (SERPINA1 target) | Korro Bio | Discovery |
| Unnamed AATD Program | AlveoGene | Pre-clinical |